公开(公告)号：WO2005019167A2

公开(公告)日：2005-03-03

申请号：PCT/US2004/026021

申请日：2004-08-11

Applicant: AMGEN, INC. ,  HULME, Christopher ,  TEMPEST, Paul ,  MA, Vu ,  NIXEY, Thomas ,  BALOW, Guity

Inventor： HULME, Christopher ,  TEMPEST, Paul ,  MA, Vu ,  NIXEY, Thomas ,  BALOW, Guity

IPC: C07D

CPC classification number: C07D257/04 ,  C07D401/06 ,  C07D403/06 ,  C07D403/10 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12

Abstract: Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula I wherein A, W, X, Z, R1-R3, and R8 are as defined in the specification, are provided. Also provided are methods of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of Formula I.

Abstract translation: 其中A，W，X，Z，R 1 -R 3和R 8如说明书中所定义的式I的新化合物或其药学上可接受的盐，互变异构体或前药。 还提供了治疗或预防受试者中黑色素浓缩激素介导的病症的方法，其包括向需要这种治疗或预​​防的受试者施用式I化合物。

公开(公告)号：WO2020132651A1

公开(公告)日：2020-06-25

申请号：PCT/US2019/068172

申请日：2019-12-20

Applicant: AMGEN INC.

Inventor： TAMAYO, Nuria A. ,  BANERJEE, Abhisek ,  BROWN, James Alexander ,  FROHN, Michael J. ,  CHEN, Jian Jeffrey ,  LI, Kexue ,  LIU, Qingyian ,  LOW, Jonathan Dante ,  MA, Vu ,  PETTUS, Liping H. ,  WALTON, Mary Catherine ,  MINATTI, Ana Elena ,  BOURBEAU, Matthew Paul ,  JIA, Lei ,  NGUYEN, Thomas T. ,  NISHIMURA, Nobuko ,  XUE, Qiufen May ,  ALLEN, John Gordon

IPC: A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  A61K31/497 ,  A61K31/444

Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

公开(公告)号：WO2020132648A1

公开(公告)日：2020-06-25

申请号：PCT/US2019/068169

申请日：2019-12-20

Applicant: AMGEN INC.

Inventor： TAMAYO, Nuria A. ,  BANERJEE, Abhisek ,  BROWN, James Alexander ,  FROHN, Michael J. ,  CHEN, Jian Jeffrey ,  LI, Kexue ,  LIU, Qingyian ,  LOW, Jonathan Dante ,  MA, Vu ,  PETTUS, Liping H. ,  WALTON, Mary Catherine ,  MINATTI, Ana Elena ,  BOURBEAU, Matthew Paul ,  JIA, Lei

IPC: A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  A61K31/506 ,  C07D419/14 ,  C07D491/044

Abstract: Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.

公开(公告)号：WO2005019240A2

公开(公告)日：2005-03-03

申请号：PCT/US2004/025970

申请日：2004-08-11

Applicant: AMGEN, INC. ,  TEMPEST, Paul ,  HULME, Christopher ,  MA, Vu

Inventor： TEMPEST, Paul ,  HULME, Christopher ,  MA, Vu

IPC: C07K

CPC classification number: C07D207/09 ,  C07D213/75 ,  C07D215/08 ,  C07D233/32 ,  C07D295/13

Abstract: Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula (I) (I) wherein W, X, Y, Z, R 3 -R 6 , and R 11 are as defined in the specification, are provided. Also provided are methods of treating or preventing a melanin concentrating hormone-mediated disorder in a subject, comprising administering to a subject in need of such treatment or prevention a compound of Formula I.

Abstract translation: 式（I）（I）的新化合物或其药学上可接受的盐，互变异构体或前药，其中W，X，Y，Z，R 3 -R 6和R 11如 提供规格。 还提供了治疗或预防受试者中黑色素浓缩激素介导的病症的方法，其包括向需要这种治疗或预​​防的受试者施用式I化合物。